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ABSTRACT 
The [11C]PIB PET tracer, originally developed for amyloid imaging, has 
been recently repurposed to quantify demyelination and remyelination in 
multiple sclerosis (MS). Myelin PET imaging however, is limited by its low 
resolution that deteriorates the quantification accuracy of white matter (WM) 
lesions. Here, we introduce a novel partial volume correction (PVC) method 
called Multiresolution–Multimodal Resolution-Recovery (MM-RR), which uses 
the wavelet transform and a synergistic statistical models to exploit MRI 
structural images to improve the resolution of [11C]PIB PET myelin imaging.  
MM-RR performance was tested on a phantom acquisition and in a 
dataset comprising [11C]PIB PET and MR T1- and T2-weighted images of 8 
healthy controls and 20 MS patients. 
For the control group, the MM-RR PET images showed an average 
increase of 5.7% in WM uptake while the grey-matter (GM) uptake remained 
constant, resulting in +31% WM/GM contrast. Furthermore, MM-RR PET 
binding maps correlated significantly with the mRNA expressions of the most 
represented proteins in the myelin sheath (R2=0.57±0.09).  
In the patient group, MM-RR PET images showed sharper lesions 
contour and significant improvement in normal-appearing tissue/WM-lesion 
contrast compared to scanner PET (contrast improvement > +40%). These 
results were consistent with MM-RR performances in phantom experiments. 
 
 
Keywords: partial volume correction, PET/MR, wavelet, myelin, multiple 
sclerosis 
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INTRODUCTION 
Multiple sclerosis (MS) is a complex neurological disorder that 
represents the first non-traumatic cause of neurological disability among 
young adults 1. MS pathophysiology is characterized by an auto-immune 
aggression of myelin sheaths resulting in demyelinated lesions and axonal 
degeneration. Myelin is however a dynamic tissue and there is strong 
evidence in animal models that myelin repair is an efficient process which 
may follow myelin insult 2. However, little is known about the dynamics of re-
myelination in patients with MS. Sensitive imaging tools are now required to 
measure myelin dynamics in-vivo to investigate spontaneous remyelination in 
MS patients and to act as biomarkers for new pro-myelinating therapies. 
Positron emission tomography (PET) with [11C]PIB was originally 
developed to image amyloid deposition in neurodegenerative disorders and 
dementia 3 and has been recently repurposed for myelin imaging in vivo in 
humans 4-6 (Figure 1). The essential steps to measure de-myelination and re-
myelination consist of lesions detection, quantification of myelin content and 
comparison between baseline and follow-up scans. In this perspective, the 
influence of partial volume effect (PVE) is relevant when detecting and 
quantifying myelin changes in lesions, considering the typical poor image 
resolution of PET and the quantification bias resulting from activity spill-in. 
The literature provides a wide range of partial volume correction (PVC) 
techniques to address the PVE in PET imaging 7. One group is represented 
by region-of-interest (ROI) based methods, which are however limited by the 
assumption of radiotracer homogeneous distribution within each ROI 7, 8. This 
condition is clearly inapplicable to MS lesions due to their heterogeneity 9, 10. 
Alternatively, voxel-based techniques like partition-based 11 and 
multiresolution methods 12, 13 are also available. A distinct final approach to 
PVC consists of incorporating a model of the system point spread function 
(PSF) into the reconstruction algorithm 14, 15. 
In this work we introduce the Multiresolution–Multimodal Resolution-
Recovery (MM-RR) method to achieve improved myelin quantification in 
[11C]PIB PET brain images by performing effective PVC using T1-weighted 
MR sequences. MM-RR stems from previous works on brain PET/MR data 13, 
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16-18 and whole-body PET/CT data 19. Similarly to these approaches, the 
relation between functional and anatomical images is exploited in a 
synergistic fashion for a realistic noise-controlled recovering of PET image 
resolution. However, the new algorithm takes a step further by modelling the 
differential sensitivity and specificity to myelin of the two modalities without the 
requirement of any anatomical segmentation which would not be applicable in 
the instance of the MS population. The ultimate clinical aim is to accurately 
quantify lesions uptake according to their degree of myelin loss and repair.  
Hence we focused the validation of the approach on clinically relevant 
metrics 19 and specifically we wanted to demonstrate that MM-RR has the 
potential to: 1) significantly improve white/grey matter contrast in normal 
[11C]PIB PET data without quantitative distortion of grey matter values; 2) 
enhance the contrast between normal appearing white matter (NAWM) and 
T2 positive perilesional and lesion signals, black holes and Gadolinium 
positive lesions 3) ameliorate the partial volume effect in small lesions and 4) 
reduce the partial volume effect around the ventricular spaces. In addition to 
the clinical investigation, the method was further validated with two additional 
analyses. Firstly, the performance of the MM-RR method was compared 
against standard PVC methods in phantom experiments. Then, similarly to 20, 
MM-RR myelin maps from healthy controls were tested against a brain-wide 
mRNA atlas of myelin associated proteins that acted as an independent 
predictor of myelin density. 
 
MATERIALS AND METHODS 
 
The Multiresolution–Multimodal Resolution-Recovery method 
The MM-RR algorithm stems from previously developed methodology 
on partial volume correction 13, 19 and denoising 21 where the structural 
information (CT or MRI) was exploited to improve the image quality of the 
functional counterpart (PET). As in these techniques, MM-RR is based on the 
wavelet decomposition of both functional and structural images.  
In the existing techniques, the high-frequency wavelet coefficients are 
transferred from the high-resolution anatomical image to the PET after 
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appropriate statistical weighting. However, prior to the wavelet decomposition, 
the anatomical image is segmented by means of tissue classification based 
on image intensity levels or by using anatomical atlases, under the 
assumption of radiotracer homogeneous distribution within each ROI. This is 
inapplicable in case of demyelinating diseases like MS, due to the 
heterogeneity of myelin content between and within lesions 9, 10. 
In the formulation presented here, the image resolution recovery 
depends on the ad-hoc modelling of the relationship between low-frequency 
information of PET and T1-weighted MR that is then used to insert high-
frequency MR information into the PET image. No a priori brain tissue 
segmentation is performed and no modelling steps are required to remove 
MRI components that are not related to myelin. The MM-RR algorithm can be 
summarized as follows: 
A. Given a T1-weighted MR and [11C]PIB PET binding map (co-registered 
to the same space), the two individual images undergo a 3D wavelet 
decomposition. A model is fitted to the scatter plot defining the 
relationship between MR and PET signal intensities at the lowest 
resolution scales (Low-resolution modelling) (Figure 2A). This 
relationship relies on the assumption of association between myelin-
bound water (as measured by T1-weighted MR) and basic myelin 
protein (as measured by [11C]PIB PET) and can be modelled by a 
linear regression through the origin with positive slope. Note that this 
relationship is proposed only for T1 relaxation and should be re-
evaluated for use with other MRI modalities. 
B. The linear model is calculated in the same fashion between the MR 
and PET coefficients for all the remaining resolution levels of the 3D 
wavelet transforms (High-resolution modelling). In this instance, given 
the loss of resolution of the PET data, the linear slope differs from the 
one at step A. (Figure 2B);  
C. For each resolution level of the 3D PET wavelet transform, new 
wavelet coefficients are calculated, rescaled from the difference 
between the models fitted in A) and B) and corrected to account for 
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MR-PET differences in term of information content and image noise 
(Figure 2C); 
D. The new PET wavelet coefficients are mapped back to the image 
space through inverse wavelet transform, generating the high-
resolution [11C]PIB PET image (2D). 
The detailed mathematical derivation of the method is reported in the  
following paragraph. 
 
The Multiresolution–Multimodal Resolution-Recovery pipeline 
 
Wavelet decomposition MM-RR algorithm 
The wavelet transform (WT) decomposes a 1D signal 𝑓(𝑥) into its high- 
and low- frequency components though a filter bank as follow 
 
𝑓(𝑥) = ∑ ∑ 𝑑𝑗(𝑘) ∙ 𝜓𝑗,𝑘(𝑥) + ∑ 𝐶𝑗(𝑘) ∙ 𝜙𝐽,𝑘(𝑥)
𝑘
𝐽
𝑗−1𝑘
 
 
[1] 
 
where 𝑗  is usually referred to as the decomposition/resolution level, 𝜓  is a 
high band-pass function and 𝜙 is a low-pass scaling function while 𝑑𝑗(𝑘) and 
𝐶𝑗(𝑘) are their resulting coefficients (respectively wavelet and low resolution 
coefficients). 
In tomographic imaging applications the input signal is no longer mono 
dimensional, therefore its components have to be represented by 3-
dimensional wavelet and scaling functions. In this case the transform 
generates 8 components from a 3D input signal while applying the one-
dimensional decomposition (high- and low- pass filters) successively along 
the three 𝑥, 𝑦, 𝑧 directions. The low-resolution coefficients resulting from the 
application of the low-pass filter to all 𝑥, 𝑦, 𝑧  directions represent the input 
signal for the second level wavelet decomposition 𝑗 = 2 . A graphical 
representation of the 3D wavelet decomposition is reported in Supplementary 
Material – Figure 1. 
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In this work, as in previously proposed PVC techniques 13, 19, we 
preferred the dual-tree complex wavelet transform (DT-CWT) 22 to the more 
widespread used dyadic wavelet transform (DWT) 23 in order to achieve better 
directionality selectivity, shift invariance and perfect reconstruction. The 
wavelet decomposition has been carried out using the 3D Complex Dual-Tree 
Discrete Wavelet Transform function from the Matlab Wavelet package 
developed by Polytechnic University, Brooklyn, NY 
(http://taco.poly.edu/WaveletSoftware/). The setting parameters comprise a 
maximum decomposition scale level of 2 and the selection of Farras and 
Kingsbury Q class filters. 
 
Scaling Factors 
Initially, both functional (PET) and anatomical (MRI) images are 
decomposed by means of the DT-CWT into several resolution elements up to 
resolution level 𝑗 = 2 and the wavelet (𝒲𝑃𝐸𝑇, 𝒲𝑀𝑅𝐼) and low resolution (ℒ𝑃𝐸𝑇, 
ℒ𝑀𝑅𝐼) coefficients collected into separate matrixes.  
The algorithm requires two scaling factors to account for the resolution 
difference between the two imaging modalities (inter-modality resolution and 
global coefficient scaling factors) and a weighting factor accounting for the 
difference between subsequent wavelet resolution levels (intra-modality 
resolution scaling factor). 
The inter-modality resolution scaling factor 𝑅  compensates for the 
difference in resolution between the two imaging modalities. It is important to 
account for this difference since the wavelet transform decomposes the image 
into several resolution levels. In case the two images being transformed do 
not have the same initial resolution, then the correspondent decomposition 
levels will be out of phase compromising the rest of the algorithm. The 
magnitude of wavelet coefficients depend on the spatial resolution of the 
image, therefore the scaling coefficient is obtained as the ratio of the 
coefficients of the original anatomical image with a smoother version which is 
degraded to PET scanner resolution through a 3-dimensional Gaussian 
filtering in image space. 
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𝑅ℒ =  
∑ ℒ𝑀𝑅𝐼
∑ ℒ𝑀𝑅𝐼𝑠
 𝑅𝒲 =  
∑ 𝒲𝑀𝑅𝐼
∑ 𝒲𝑀𝑅𝐼𝑠
 [2] 
 
The global coefficient scaling factor 𝐺  compensates for the difference in 
intensity between PET and MRI coefficients. Note that in Eq [3] the PET 
coefficients are multiplied with the inter-modality resolution scaling factor 𝑅 for 
consistency purpose. 
 
𝐺ℒ =  
𝑅ℒ ∙ ∑ ℒ𝑃𝐸𝑇
∑ ℒ𝑀𝑅𝐼
 𝐺𝒲 =  
𝑅𝒲 ∙ ∑ 𝒲𝑃𝐸𝑇
∑ 𝒲𝑀𝑅𝐼
 [3] 
 
The PET and MRI wavelets and low-resolution coefficients are then 
respectively multiplied within each iterative step by the inter-modality 
resolution and the global coefficient scaling factors that remain unvaried 
during the whole iterative procedure outlined in the next section.  
 
MM-RR algorithm  
The first step of the algorithm consists of creating a correlation model 
between the functional and structural information taking into account only the 
low-resolution coefficients (Figure 2A). This step is also called low-resolution 
modelling and corresponds to: 
 
ℒ𝑚𝑜𝑑𝑒𝑙 = 𝛼 ∙ 𝐺ℒ ∙ ℒ𝑀𝑅𝐼 + 𝛽 [4] 
 
𝑟𝑒𝑠𝑖𝑑𝑢𝑎𝑙𝑠ℒ = 𝐺
ℒ ∙ ℒ𝑀𝑅𝐼 −  ℒ𝑚𝑜𝑑𝑒𝑙 [5] 
 
where 𝛼 and 𝛽 are the slope and intercept of MR and PET regression at low-
resolution scales (ℒ𝑚𝑜𝑑𝑒𝑙), stored together with the 𝑟𝑒𝑠𝑖𝑑𝑢𝑎𝑙𝑠ℒ before moving 
on with the analysis of the wavelet coefficients.  
In the following iterative steps, each set of wavelet coefficients related 
to a specific direction and resolution level is analysed separately. For each set 
a correlation analysis is performed between the functional and structural high-
resolution wavelet coefficients (𝒲𝑀𝑅𝐼 , 𝒲𝑃𝐸𝑇). The coefficients that fall in the 
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second and fourth quadrant of the Cartesian graph (Figure 2B) are discarded 
before calculating the correlation model. These coefficients with negative 
correlation refers to image component that are present in only one image 
modality thus resulting from image noise.  
 
𝒲𝑚𝑜𝑑𝑒𝑙 = 𝛼 ∙ 𝐺𝒲 ∙ 𝒲𝑀𝑅𝐼 + 𝛽 
 
[6] 
 
Once the linear model is computed, the residuals are calculated and 
stored (Figure 2B).  
 
𝑟𝑒𝑠𝑖𝑑𝑢𝑎𝑙𝑠𝒲 = 𝐺
𝒲 ∙ 𝒲𝑀𝑅𝐼 −  𝒲𝑚𝑜𝑑𝑒𝑙 [7] 
 
The residuals are then added to the correlation model (ℒ𝑚𝑜𝑑𝑒𝑙) obtained from 
the low-resolution coefficients at the first step to obtain the final coefficients of 
the improved PET image (Figure 2C). The initial model containing information 
on low-resolution uniform activity distribution is integrated with its missing 
high-resolution information for the specific set of coefficients described by the 
residuals: 
 
𝒲𝑛𝑒𝑤_𝑃𝐸𝑇 = ℒ𝑚𝑜𝑑𝑒𝑙 + 𝑟𝑒𝑠𝑖𝑑𝑢𝑎𝑙𝑠𝒲 [8] 
 
To note that in Eq [8], the correlation model obtained with low-resolution 
coefficients of Eq [4] is used as foundation in the computation of the 
coefficients for the new high resolution PET. Since the magnitude of the 
coefficients increases as the decomposition proceeds to finer resolution 
levels, an intra-modality resolution scaling factor Λ  accounting for this 
difference is needed. 
We used a robust measure of the noise variance computed for each 
resolution level (𝜎ℒ and 𝜎𝒲) to account for this scaling factor. Precisely we 
computed the median absolute deviation MAD which is then divided by 
0.6745 for calibration purposes 24, 25. 
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𝜎ℒ = 𝑀𝐴𝐷{𝑟𝑒𝑠𝑖𝑑𝑢𝑎𝑙ℒ} 0.6745⁄  [9] 
 
𝜎𝒲 = 𝑀𝐴𝐷{𝑟𝑒𝑠𝑖𝑑𝑢𝑎𝑙𝒲} 0.6745⁄  [10] 
 
Once the measures of the noise variance are known, the intra-modality 
resolution scaling factor Λ  is computed as their ratio between different 
resolution levels as in Eq [11] and integrated in the final model of Eq [8] to 
obtain Eq [12]  
 
Λ = 𝜎𝒲 𝜎ℒ⁄  [11] 
 
𝒲𝑛𝑒𝑤_𝑃𝐸𝑇 = ℒ𝑚𝑜𝑑𝑒𝑙 + Λ ∙ 𝑟𝑒𝑠𝑖𝑑𝑢𝑎𝑙𝑠𝒲 [12] 
 
Once the new wavelet coefficients (𝒲𝑛𝑒𝑤_𝑃𝐸𝑇) are calculated iteratively for all 
the wavelet quadrants, an inverse wavelet transform is performed to obtain 
the new high resolution PET image (Figure 2D).  
 
 
Phantom Experiments 
Given the impossibility to generate simulated PET/MR myelin imaging 
data accounting for the complex biology of the brain tissues, the evaluation of 
the MM-RR method was done using the PET/CT phantom data generated in 
19 where there is a similar positive association between the PET fluorine 
signal and the CT measured density.   
Briefly, the NEMA IEC body phantom with six spheres of different 
volumes (range from 0.5 cm3 to 26.5 cm3) was considered. Compartments 
were filled with both iodinated contrast media (CM) Omnipaque300TM (300 
mg/ml organic Iodine) and radioactive tracer 18F-Fluoride. Two different 
experiments changing the layout of CT and PET contrasts were performed, 
accounting for possible mismatches between functional and anatomical 
images (Figure 3A). Full experimental details are reported in the original 
references 19. 
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The resulting images were then processed with the MM-RR algorithm, 
with the CT image used instead of the MRI as the high-resolution low-
specificity reference image for the algorithm. In addition, the same data were 
reconstructed with the inclusion of a Point Spread Function (PSF) model into 
the standard OSEM algorithm (GE Q.Core VuePoint FX-S, henceforth called 
PET-PSF). For comparative purposes, PVC with the SFS-RR algorithm was 
also included 19.  
 Consistently with previous work 19, the performance of PVC methods 
was expressed in term of Root Mean Square Error (RMSE) and Contrast to 
Noise Ratio (CNR). 
 
Dataset 
The MM-RR technique was tested with two measured datasets from 
the same study comprising [11C]PIB PET and structural T1-weighted MR 
images. For the first part of the study, 8 healthy control subjects (3 male, 5 
female, age: 31.6 ± 6.3 years) were enrolled 20. Inclusion criteria consisted in 
an age between 18 and 55 years and the absence of any known neurological 
or psychiatric condition.  
The second set comprised of 20 relapsing-remitting MS patients age- 
and gender-matched to healthy controls (7 male, 13 female, age: 32.3 ± 5.6 
years) with at least one gadolinium enhancing (Gd+) lesion over 6mm in 
diameter on magnetic resonance imaging (MRI) at study entry 6.  
For both studies, ethical approval was granted by the ethics committee 
of the Pite-Salpetriere Hospital (Approval No. P080503) and informed consent 
was obtained from all participants. This study was conducted according to the 
Declaration of Helsinki. 
 
Positron Emission Tomography and Magnetic Resonance Imaging 
All PET scans were performed on the brain dedicated PET research 
tomograph ECAT-HRRT (CPS Innovations, Knoxville, TN, USA). This high 
resolution scanner achieves an intra-slice spatial resolution of ~2.5 mm full 
width at half maximum, with 25 cm and 31.2 cm of axial and transaxial field of 
view 26. 
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The 90-minute emission scan was initiated coincident with a 1-minute 
intravenous bolus injection of [11C]PIB (mean 358 ± 34 MBq). There were no 
differences between healthy controls and patients in term of injected 
radioactivity or specific activity 6. Images were reconstructed using the 3D 
ordinary Poisson ordered subset expectation maximization algorithm 
(POSEM) 27 implementing point spread function (PSF) modelling up to 10 
iterations. An additional smoothing filter implementing the PSF was applied to 
the reconstructed images to remove image inhomogeneity and spiky artefacts 
28.  
The resulting dynamic PET images consisted of 25 frames of data (6 × 
1, 6 × 2, 4 × 3, 6 × 5, 3 × 10 minutes) with a voxel size of 1.22 mm × 1.22 mm 
× 1.22 mm. Inter-frame subject motion correction was applied by realigning 
each PET frame to a common reference space through a procedure similar to 
those reported by Montgomery et al 29. Data were corrected for carbon-11 
decay. A reference region was determined using previously published 
methodology developed specifically for [11C]PIB that uses a supervised 
clustering approach to determine a set of grey matter voxels with kinetics that 
are the closest to a predefined set of normative dynamics 30. The average 
time-activity curve of these voxels was used as input for the Logan plot to 
derive parametric maps of volume of distribution (DVR)31. We refer to 
Veronese et al 20 for a detailed description of the PET [11C]PIB dynamic 
quantification. 
In addition to the PET acquisition, MR images of all subjects were 
collected using a 3T Siemens system (Siemens, Erlangen, Germany; TRIO 
32-channel TIM system). Specifically, 3D T1-weighted MPRAGE, T2-weighted 
(T2-w) and 3D FLAIR sequences were performed for all subjects while 
patients had additional pre- and post- gadolinium T1 spin-echo sequences. 
Only the T1 weighted images were used for PVC using MM-RR. Lesions were 
segmented on T2-w images with reference to co-registered FLAIR scans. 
For each subject, T2- and T1- weighted images were co-registered to 
the PET space using a rigid transformation using Flirt 
(http://fsl.fmrib.ox.ac.uk/fsl/) maintaining PET data in its original space and 
avoiding further loss of resolution due to interpolation. Using VBM8 toolbox 
(hhttp://dbm.neuro.uni-jena.de/vbm/download/) and FIRST 
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(http://fsl.fmrib.ox.ac.uk/fsl/), image voxels were automatically classified as 
grey matter (GM), white matter (WM) and cerebrospinal fluid (CSF) using a 
tissue probability threshold of 90%. The quality of all the image segmentations 
and coregistrations was assessed via visual inspection by an experienced 
neuroimaging scientist. 
Additional regions of interest (ROIs) were manually defined on patient 
images by an experienced neurologist using the co-registered information 
from the T2- weighted and T1-weighted images. The ROIs were classified as 
follow: 1) GM; 2) normal-appearing WM; 3) perilesional WM; 4) lesion WM; 5) 
black holes and 6) Gadolinium enhancing (Gd+) lesions. Only lesions above 
2.5 mm (corresponding to the resolution of the PET-camera) were retained as 
effective ROI. 
 
Image analysis and evaluation 
Qualitative and quantitative evaluations were carried out comparing the 
original data, here labelled as “Scanner PET” images with the output of the 
resolution recovery procedure, here named “MM-RR PET”, in order to 
evaluate the performance of the MM-RR algorithm. 
In the first instance, we analysed the images of the healthy subjects to 
evaluate resolution recovery and to control for any bias that may have been 
introduced. For each subject we calculated the average [11C]PIB DVR in three 
ROIs (GM, WM and whole brain respectively) and the mean and standard 
deviation of all subjects were compared between Scanner and MM-RR PET. 
As an additional check, we calculated the [11C]PIB DVR as a function of the 
distance from the cerebral spinal fluid for both WM and GM ROIs as a loss of 
signal near the ventricles was evident in the original data as a result of PVE 
20. This is very relevant for the quantification of all lesions close to these 
boundaries. Finally, for a quantitative evaluation of resolution recovery, a 
contrast analysis was performed taking into consideration the GM/WM 
contrast in small spherical regions of 2.5, 5, 7.5 and 10 mm diameter. For 
each subject a pair of random regions was drawn on the GM and WM 
segmented on the T1-weighted images. Both ROIs were then moved to the 
PET images (Scanner and MM-RR) and the mean of voxel estimates within 
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each region was computed (𝑊𝑀𝑅𝑂𝐼 ,  𝐺𝑀𝑅𝑂𝐼 ) and the mean local contrast 
calculated as 
 
𝑚𝑙𝑐% =
𝑊𝑀𝑅𝑂𝐼−𝐺𝑀𝑅𝑂𝐼
𝐺𝑀𝑅𝑂𝐼
∙ 100 
[13] 
 
The procedure was repeated up to 500 times for each sphere diameter size 
and mean and variability of 𝑚𝑐𝑙% were compared between different ROI sizes 
as well as between Scanner and MM-RR PET. 
For the patient group, we compared the average [11C]PIB DVR with the 
same statistical methodology used for the healthy subjects group focusing 
however on clinically relevant ROIs, specifically the normal-appearing WM, 
perilesional area, lesions, black holes and Gadolinium enhancing (Gd+) 
lesions. These ROIs were chosen consistently with previous studies 6. 
Additionally, we performed a correlation analysis between the average 
[11C]PIB DVR and the lesional volumes to check whether the effect of the 
PVC depended on the size of the lesion, as one would have expected. To 
perform this type of analysis we grouped all the lesions of all the patients 
according to their volumes. Then, for each lesions size, we calculated the 
average [11C]PIB DVR of all patients’ lesions of that specific volume. The 
analysis was limited to WM lesions, to control for the effect of tissue 
surrounding contrast on PVC. 
 
MM-RR PET myelin mapping: correlation with myelin associated protein 
mRNA expressions 
In order to evaluate the validity of the myelin maps produced by MM-RR 
method, [11C]PIB PET maps derived from the healthy control group (both MM-
RR and Scanner PET) were tested against the brain mRNA expression atlas 
of a set of myelin-associated proteins contained in the Allen Human Brain 
Atlas 32. We have previously shown that these mRNA maps are highly 
predictive of protein levels in-vivo measured with PET for all those transcripts 
that do not undergo significant post-transcriptional modifications 33, a 
condition that is met for the myelin system 20. The comparison between 
imaging and gene expressions was performed by correlation analysis at the 
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voxel level in stereotaxic MNI (Montreal Neurological Institute) coordinate 
accordingly to MENGA pipeline 34 (https://www.nitrc.org/projects/menga/).  
The proteins considered for the analysis were selected based on their 
prevalence in the myelin sheath 35: myelin associated glycoprotein (MAG), 
myelin basic protein (MBP), proteolipid protein-1 (PLP1), 2',3'-Cyclic-
nucleotide 3'-phosphodiesterase  (CNP), myelin oligodendrocyte glycoprotein  
(MOG), and oligodendrocyte basic protein (MOBP). To exclude for spurious 
correlations, [11C]PIB imaging data were also compared with a series of non-
myelin proteins including dopamine D2 receptor (DRD2), 5HT1A serotonin 
receptor (HTR1A), brain-derived neurotrophic factor (BDNF), and Aquaporin 
4  (AQP4). 
 
 
RESULTS 
 
Phantom Data 
The performance of the PVC methods is summarized in Figure 3.  
As expected, the smaller the sphere, the bigger the bias in the activity 
estimation, regardless of the PVC method used. 
Given the lack of segmented anatomical information, as expected the 
performance of MM-RR are inferior to the one of SFS-RR (RMSE relative 
difference +10%±11%; CNR relative difference -9%±13%) but comparable 
with the PSF reconstruction method (RMSE relative difference 0%±4%; CNR 
relative difference +6%±7%) across spheres. Compared to scanner PET. The 
images refer to a representative healthy control. The MM-RR PET images 
show sharper contours compared to the Scanner PET and better WM 
definition. 
The qualitative improvement of the MM-RR [11C]PIB DVR maps is 
confirmed by the quantitative analysis. Figure 4B reports the comparison of 
the three tissue ROIs (whole brain, GM and WM) in the healthy control 
dataset. Each box collects the mean value for the specific ROI of all the 
healthy subjects. The average DVR in the WM is 5.7% higher for the MM-RR 
PET compared to the Scanner PET (Paired t-test p<0.001). The average DVR 
in the GM is comparable between Scanner PET and MM-RR PET (Paired t-
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test p=0.72) confirming the lack of quantitative distortion in the latter. 
Moreover, the resolution recovery does not come at the cost of increased 
noise as the standard deviations of the two imaging modalities are 
comparable for all the three ROIs (F-test p>0.35 for all ROIs).  
A quantitative evaluation of the improved image quality achieved with 
the MM-RR algorithm is shown by the WM/GM contrast analysis 
(Supplementary Material – Figure 2). The MM-RR PET images show an 
average increase of 30% in WM/GM contrast compared to Scanner PET, 
corresponding to an average [11C]PIB DVR WM/GM ratio greater than 15%. 
These results are independent from ROI size; please note that the highest 
signal improvement is reported for the smallest ROI (diameter 2.5 mm) with a 
46% increase in WM/GM contrast compared to Scanner PET.  
A quantitative measure of the PVC that can be achieved with MM-RR 
is shown in Figure 5, where the DVR for WM and GM is displayed as a 
function of the distance from the CSF. In GM, [11C]PIB DVR estimates are 
comparable within the first 3 mm (mean relative difference of 3%±2%), after 
which MM-RR PET returns lower values compared to Scanner PET (mean 
relative difference -9%±1% at 5mm). To note that the further from the CSF 
the lower the number of voxels, especially in the GM, which introduces 
an additional element of variability. For the WM, instead, the highest 
discrepancy between Scanner and MM-RR [11C]PIB DVR estimates is found 
within 5 mm of distance from CSF (up to 31% in mean relative difference), 
while the two images become comparable as the distance increases (mean 
relative difference +2%±1%). This suggests that the recovered resolution 
concurs in correcting for spill-out effect in the WM border area. This 
corresponds to both WM/GM and WM/CSF boundaries. This is of 
relevance given that neurodegeneration around the ventricles is an early 
process in the pathophysiology of MS.  
 
Correlation with myelin associated protein mRNA expressions 
MM-RR did not affect the level of cross-correlation between imaging 
and genomic data (Figure 6A).  High-resolution maps returned the same 
levels of correlation with the mRNA expressions of myelin associated proteins 
of standard resolution maps (Paired t-test p<0.05; mean relative difference: -
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1%±4%) (Figure 6B). Genomic vs imaging cross-correlation was significant for 
all tested cases (p<0.05), ranging from R2 = 0.48 to R2 = 0.67. On the 
opposite, for both resolution levels, imaging vs genomic cross-correlation was 
not significant when non-myelin associated proteins were considered 
(R2<0.26 for all subjects and all genes) (Figure 6B). 
 
Application to [11C]PIB PET myelin imaging in patients with MS 
Figures 7 reports the impact of the MM-RR application to the MS 
patient dataset. Figure 7A provides an example of the improved lesion 
detectability achieved with the MM-RR algorithm compared to the Scanner 
PET. The images refer to a representative MS patient. As for the healthy 
control in Figure 4A, the MM-RR PET images show sharper contours 
compared to the Scanner PET. Additionally, a noticeable improvement in 
lesion detectability can be appreciated in the two representative lesions 
(zoomed in the red circle). Additional specific example for Gadolinium 
enhanced lesion is reported in Figure 6 – Supplementary material. 
The quantitative impact of the MM-RR application on patient images is 
reported in Figure 7B. As previously done for healthy controls (Figure 4B), 
each box collects the mean value for a specific clinically relevant ROI for all 
the patients. The average [11C]PIB DVR in the lesional tissue (T2-w lesions, 
black holes and Gadolinium enhancing lesions) is significantly lower for the 
MM-RR PET (mean difference 4-12%, p<0.05). On the other hand, there is a 
consistent increase of the DVR in the perilesional area, normal-appearing WM 
and GM (Paired t-test p<0.001) up to 5%. Compared to Scanner PET, the 
average normal-appearing WM/lesion contrast improves in high-resolution 
PET: +34% for T2-w lesions, +39% for black holes and +101% for Gadolinium 
enhancing lesions. As for the analysis of the healthy control dataset, the 
standard deviation of the two imaging modalities is comparable for all the 
ROIs (F-test p>0.87 for all ROIs). 
These results are then consistent with the resolution analysis carried 
out on the collected lesions of varying size (Supplementary Material – Figure 
3). Lesions on the MM-RR PET tend to have lower [11C]PIB DVR than the 
Scanner PET ones but this difference is more evident on small lesions, while 
for big lesions the two modalities produce very similar DVRs. 
 18 
 
 
Application to [18F]FDOPA PET imaging 
The robustness to anatomical and functional mismatch of PVC 
wavelet-based approached has been previously demonstrated 19. However, 
an additional test was performed to ensure that no bias or artefacts are 
introduced when the structural and functional signals are not related. We 
applied the MM-RR algorithm to a sample [18F]FDOPA PET/MR scan of a 
healthy subject (www.nitrc.org/projects/spmtemplates/) where the anatomical 
information had not relation with the PET signal located in the basal ganglia. 
As predicted, no artefacts are introduced after application of MM-RR 
(Supplementary Material – Figure 4). 
 
DISCUSSION 
MM-RR has been developed to give a mathematical account of the 
better specificity to myelin of PET at low resolution as well as the good 
precision of MRI at finer resolution scales. The application to clinical data 
showed that MM-RR led to improved WM/GM contrast compared to Scanner 
PET imaging. In MS patients, MM-RR allowed a better signal characterization 
of [11C]PIB PET in lesions. One main advantage of MM-RR methods over 
more conventional approach is straightforward applicability without 
prior knowledge or pre-processing. Standard PVC techniques often 
require ad-hoc measurements of the scanner PSF or tissue 
classification and/or segmentation, which cannot be easily performed 
on such heterogeneous lesion distribution.  
Our results on the healthy control dataset showed a qualitative 
significant improvement especially in the delineation of WM structures and an 
average 30% increase in contrast between white and grey matter at the 
expenses of no quantification bias or noise increase. The signal recovery and 
good noise control assessed in the healthy controls were then reflected into 
patient images that demonstrated lesions with sharper and better-defined 
contours and the resulting accurate quantification of [11C]PIB DVR in different 
lesion types and perilesional areas.  
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Additional validations of the method included application to phantom 
data and comparison of MM-RR myelin map with genomic dataset. In the first 
case, MM-RR demonstrated to return comparable PVC results to PSF 
reconstruction method but worse performances in term of bias and image 
contrast than the atlas-based approach implemented in SFS which is 
expected given the stronger and more informed prior implemented by SFS 
compared to MM-RR.  Please note that in this work the resolution 
recovery algorithm was applied to clinical data that were reconstructed 
with PSF inclusion and POESM settings that were optimized according 
to our previous work 5. The application of resolution recovery methods 
to parametric maps of lower quality may degrade the final quality of the 
images.  
The reliability of the MM-RR method was confirmed by the genomic 
analysis as MM-RR returned high-resolution [11C]PIB maps without altering 
the degree of correlation with the myelin-associated protein gene expressions.  
The effectiveness of the MM-RR relies on the validity of some important 
assumptions. First of all the presence of a shared myelin content between 
[11C]PIB PET and T1w MR imaging. This relationship allows the identification 
of the low-resolution model in wavelet space, which is at the basis of the 
fusion between the two modalities. This assumption limits the MM-RR 
extendibility to those cases when the information content of both anatomical 
and functional images is mismatched. At the same time, MM-RR requires the 
accurate spatial coregistration of both modalities. In case of misalignment, 
MM-RR method can lead to image artefacts (Supplementary Material – Figure 
5). This result was quite expected as all PVC techniques which relies on 
anatomical information are naturally sensitive to mis-registration errors. 
Accurate image co-registration should be achieved prior PVC application. The 
choice of PVC technique should depend on application and image co-
registration reliability 36. 
In order to assess the robustness of the algorithm towards possible 
artefacts due to mismatch between anatomical and functional images, we 
additionally tested the algorithm using [18F]FDOPA PET and T1 MR images 
from healthy subjects. Since T1 sequences are not sensitive to dopamine, 
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one would not expect significant changes in the final PET images as the 
analysis demonstrated. It follows that MM-RR method can only be applied 
when functional and structural data share an association to the biological 
target. In this investigation the structural information was provided by T1-w 
images; however, this MRI sequence is not the most specific to myelin 
content. Future work will consider the use of more myelin-sensitive MR 
imaging sequences such as the Magnetic Transfer Imaging (MTR)37, 38 or the 
Multi-Component Driven Equilibrium Single Pulse Observation of T1 (mc-
DESPOT)39, 40.  
 
CONCLUSION 
We have developed a robust multimodal methodology for the 
quantitative resolution recovery of brain [11C]PIB PET data, here specifically 
designed for myelin imaging, and tested it on a set of clinical healthy controls 
and MS patients data. The technique produces images with significantly 
improved quantitative properties and visual quality and it is of straightforward 
and rapid application. The work presented here is highly relevant for the newly 
introduced PET-MRI scanners as it presents one of the first synergistic 
approaches combining PET and MRI data for the same target. 
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FIGURE LEGENDS 
Figure 1 – Representation of [11C]PIB PET myelin signal. A) Axon 
structure with visible alternation of myelin lipid bilayer and myelin water 
content; B) detailed representation of myelin structure where the lipid bilayers 
and the myelin basic proteins (MBP) in between are highlighted; C) schematic 
representation of [11C]PIB PET myelin signal: [11C]PIB, in analogy to its 
interaction to amyloid fibrils, might have multiple interactions with the myelin 
structure: on one side it might get trapped into β-sheet structures of myelin 
proteins such as MBP 41-43, and on the other side be highly soluble in the 
myelin associated lipid bilayer 44. 
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Figure 2 - Graphical representation of the MM-RR algorithm. A) wavelet 
decomposition and model definition of the relationship between MR and PET 
signals at low resolution scales (Low-resolution modelling); B) model definition 
of the relationship between MR and PET high-resolution coefficients (High-
resolution modelling); C) definition of new wavelet coefficients from the 
models defined in A) and B) after appropriate scaling and de-noising; D) 
inverse wavelet transform of the final wavelet coefficients originates the 
improved PET image. To note that the wavelet coefficients in XY plots are 
unitless. 
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Figure 3 – Phantom Experiment. A) [18F]Fluoride PET/CT transaxial images 
of three different phantom experiment acquisitions (one for each line). 
Alongside the CT image (1st column) are three different type of functional 
images: scanner PET images (2nd column), images resulting from the 
inclusion of a PSF model into the reconstruction (3rd column), images 
resulting after the application of the SFS resolution recovery algorithm (4th 
column), and images resulting after the application of the MMRR resolution 
recovery algorithm (5th column).  B-D) Root mean square error and noise 
analysis. For each sphere (S1-S6) four values corresponding to images 
obtained with different modalities are reported: Scanner PET (black circle), 
PET with PSF reconstruction (grey triangle), PET corrected with SFS-RR 
algorithm (white diamond), and PET corrected with MM-RR algorithm (black 
cross). A) Root mean square error for the six spheres obtained as an average 
between the two phantom experiments. B-C) Contrast to noise ratio computed 
for each sphere against a uniform region in the phantom background. 
Representative phantom figures are reported next to graph for reference 
purposes. 
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Figure 4 – Scanner and MM-RR PET in a representative healthy control. 
A) Images: Left column MRI images; central column Scanner PET; right 
column MM-RR PET. PET colorbars indicate DVR estimates (unitless). B) 
[11C]PIB DVR values: The box-plot diagrams show the median (middle line) 
and range of DVR values for the healthy control group in three different ROIs 
(from left to right: whole brain, grey matter, white matter). The table reports 
the numerical value of mean and standard deviation for each box. ** indicates 
p-value<0.001 
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Figure 5 - The graph reports the [11C]PIB DVR values measured for white 
matter (white markers) and grey matter (grey markers) as function of the 
distance from the cerebral spinal fluid (CSF). Lines with circle markers 
refer to the Scanner PET and the lines with triangle markers refer to the MM-
RR PET. Light grey markers on grey matter lines refer to significant lower 
fraction of grey matter tissue compared to the sample closer to the CSF. 
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Figure 6 – Comparison between [11C]PET myelin imaging and genomics. Panel 
A compares imaging vs genomic cross-correlation between Scanner and MM-RR 
PET images. All subjects and proteins are reported. Blue circles refer to myelin 
associated proteins (i.e. MAG, MBP, PLP1, CNP, MOG and MOBP) while red circles 
to non-myelin associated proteins (i.e. DRD2, HTR1A, BDNF and AQP4). Panel B 
compares mean±SD imaging vs genomic cross-correlation between subjects for MM-
RR and Scanner PET resolution respectively. Blue bars refer to myelin associated 
proteins. Red bars refer to non-myelin associated proteins. Bright bars refer MM_RR 
resolution PET. Light bars refer to Scanner resolution PET. All the correlations above 
significance threshold line result statistically significant (pvalue<0.05). 
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Figure 7 - Axial and sagittal views from a representative MS patient. A) 
Images: From left to right: MRI images; Scanner PET; MM-RR PET; zooms of 
the area delimited in the MRI image with a red circle. PET colorbars indicate 
DVR estimates (unitless). B) [11C]PIB DVR values: The box-plot diagrams 
show the median (middle line) and range of DVR for the healthy control group 
in three different ROIs (from left to right: grey matter GM, normal-appearing 
white matter NAWM, Perilesions, T2-w lesions, Black Holes, Gad enhancing 
lesions). The table reports the numerical value of mean and standard 
deviation for each box. ** indicates p-value<0.001. * indicates p-value<0.05 
 
